Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC

“We aim to bring together advanced diagnostics and transformative medicines, with the goal of benefitting many Alzheimer's patients through earlier detection and intervention,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Our presentations at AAIC will feature data from our expanding Alzheimer’s disease portfolio, including investigational trontinemab, neuroinflammatory approaches and blood-based diagnostics.”

“With the approval of Elecsys pTau217, our third Alzheimer’s blood test, across both primary and secondary care, we are making timely and definitive diagnosis more accessible than ever before,” said Matt Sause, CEO of Roche Diagnostics." For too long, this has been out of reach for the vast majority of patients. As a result, millions have been left without the answers, care and support they need. That is now changing, as blood-based testing transforms the diagnosis of Alzheimer’s disease."

Pharmaceuticals
Trontinemab Featured Research Session
A 90-minute Featured Research Session will showcase five oral presentations focused on the latest progress in the development of trontinemab, an investigational Brainshuttle^TM bispecific 2+1 amyloid-beta targeting monoclonal antibody. Presenters will share new long-term safety, amyloid removal and biomarker data from the Phase Ib/IIa Brainshuttle AD open-label extension study. Modelling from this study has informed the dosing regimen for the ongoing Phase III TRONTIER 1 and 2 studies in early symptomatic Alzheimer’s disease.

For the first time, Roche will also share the design of PrevenTRON, a Phase III study investigating trontinemab in preclinical Alzheimer’s disease. PrevenTRON is planning to recruit cognitively unimpaired individuals at high risk of progression to symptomatic Alzheimer’s, and investigators are using Roche’s Elecsys pTau217 blood test to help identify potential study participants.

NLRP3 inhibition Invited Perspectives Session
In addition to targeting amyloid with trontinemab, Roche is exploring multiple other investigational therapeutic approaches to tackle the complexity of neurodegenerative diseases. AAIC has invited Roche to present a Perspectives Session on the NLRP3 inflammasome in Alzheimer’s disease. Emerging preclinical and clinical data on the immunomodulatory effects of NLRP3 inhibition in neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease will also be presented.

Diagnostics
Roche’s Elecsys pTau217 blood test recently received CE mark certification as both a rule-in and rule-out test of amyloid pathology to aid in Alzheimer’s disease diagnosis, and data will be presented evaluating the test’s performance in primary and secondary care settings. In addition, new data will be presented for the approved Elecsys pTau181 blood test for ruling out Alzheimer’s disease, which explores sample stability under different storage conditions and test performance across large, diverse, cognitively impaired patient populations to support implementation of the test in routine clinical practice.

Roche is sponsoring a symposium “Closing the Diagnostic Gap: Utilizing pTau217 for Scalable Alzheimer’s Disease Diagnosis” on Sunday 12 July at 12:30-13:45 BST at the Crowne Plaza London Docklands Hotel. The symposium will discuss the evolving role of blood-based biomarkers in the early detection and diagnosis of Alzheimer’s disease, including the potential of scalable blood testing approaches designed to help reduce diagnostic barriers, enable earlier identification of individuals at risk, and support broader access to disease-modifying therapies in clinical practice. 

Overview of key presentations featuring Roche pharmaceuticals and diagnostics:

About Roche in Alzheimer’s
With more than two decades of scientific research in Alzheimer’s disease, Roche is working towards a day when we can detect, diagnose, monitor and treat the condition earlier, so we can slow, stop or even prevent its progression.

Today, Roche’s Alzheimer’s disease portfolio spans several investigational medicines for different targets, types and stages of the disease, including trontinemab, nivegacetor and RG6627. On the diagnostics side, it covers approved and investigational digital and blood-based tests and cerebrospinal fluid (CSF) assays, including Elecsys pTau181, pTau217 and ApoE4.

Addressing the global burden of Alzheimer’s disease requires more than innovative tests and treatments. This is why Roche partners with clinicians, scientists, patient advocates, policymakers and health systems to help ensure that advances in Alzheimer’s disease research translate into benefits for millions of people worldwide.

About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Roche Investor Relations

Investor Relations North America

Attachment